Abstract
Somatostatin analogues (SSA) are widely used in the treatment of patients with functioning and non-functioning well-differentiated neuroendocrine tumors (NET). The antiproliferative activity of SSA in NETs has been confirmed in two randomized placebo-controlled trials. The PROMID trial was the study assessing the effect of octreotide LAR on the control of tumor growth in patients with metastatic, well-differentiated mostly G1 midgut NETs, but not pancreatic NET. The Clarinet trial evaluated the effect of another analogue of SST - lanreotide autogel (AG) 120mg sc in patients with metastatic, well- or moderately differentiated, non-functional enteropancreatic NETs including also pancreatic NET G1/G2 (Ki-67 index < 10%), nonfunctioning, SSTR-positive There are only a few retrospectives study evaluated the efficacy of octreotide LAR 30mg in pan NET.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
